ReviewFrontiers in endocrinology2020
Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- PCOS and breast cancer risk: hormonal modulation and epidemiological trends.Reproductive health · 2026Review
- Global analysis of actionable genomic alterations in thyroid cancer and precision-based pharmacogenomic strategies.Frontiers in pharmacology · 2025Article
- Identification of the Shared Gene Signatures and Pathways Between Polycystic Ovary Syndrome and Endometrial Cancer Using Bioinformatics and Mendelian Randomization Analyses.International journal of women's health · 2025Article
- Global Research Trends on Inflammation in Polycystic Ovary Syndrome: Insights From Bibliometric and Scientometric Analysis.International journal of endocrinology · 2025Article
- Polycystic Ovary Syndrome and Ferroptosis: Following Ariadne's Thread.Biomedicines · 2024Article
- Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies.Heliyon · 2024Article
- Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses.Scientific reports · 2024Article
- Exploring the therapeutic mechanisms of Yikang decoction in polycystic ovary syndrome: an integration of GEO datasets, network pharmacology, and molecular dynamics simulations.Frontiers in medicine · 2024Article
- The pharmacoepigenetic paradigm in cancer treatment.Frontiers in pharmacology · 2024Review
- Comparative analysis of serum and saliva samples using Raman spectroscopy: a high-throughput investigation in patients with polycystic ovary syndrome and periodontitis.BMC women's health · 2023Article
- A New Approach to Polycystic Ovary Syndrome and Related Cardio-metabolic Risk Factors: Dietary Polyphenols.Current nutrition reports · 2023Review
- Integrated multi-omics analysis reveals the molecular interplay between circadian clocks and cancer pathogenesis.Scientific reports · 2023Article
- Pathophysiological Effects of Contemporary Lifestyle on Evolutionary-Conserved Survival Mechanisms in Polycystic Ovary Syndrome.Life (Basel, Switzerland) · 2023Review
- Tracing the pathways and mechanisms involved in medicinal uses of flaxseed with computational methods and bioinformatics tools.Frontiers in chemistry · 2023Article
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis.Journal of ovarian research · 2022Article
- Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment.International journal of environmental research and public health · 2022Review
- Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Epidemiological findings revealed that women with PCOS are prone to develop certain cancer types due to their shared metabolic and endocrine abnormalities. However, the mechanism that relates PCOS and oncogenesis has not been addressed. Herein, in this review article the genomic status, transcriptional and protein profiles of 264 strongly PCOS related genes (PRG) were evaluated in endometrial cancer (EC), ovarian cancer (OV) and breast cancer (BC) exploring oncogenic databases. The genomic alterations of PRG were significantly higher when compared with a set of non-diseases genes in all cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.